You are currently viewing archive.bio.org. Head to our home page to check out our fresh new look!

Pfizer Executive Peter Corr, Ph.D., to Deliver Keynote at BIO CEO & Investor Conference

WASHINGTON, D.C. (February 11, 2005) -- Peter B. Corr, Ph.D., Senior Vice President for Science and Technology at Pfizer, Inc., will make the keynote address for the luncheon on the second day of the annual BIO CEO & Investor Conference in New York City.  His address will begin at 12:30 pm in the Grand Ballroom of the Waldorf=Astoria on Thursday, February 24. 

Now in its seventh year, the conference is the premiere industry investors’ conference and will include more than 200 presenting companies from the U.S., Europe and Canada.  The conference will also feature “focused” panel discussions with company executives along with clinical, financial and regulatory experts who will present their views on the most promising developments in medical biotechnology for diseases and medical conditions such as hepatitis, lupus, cancer, HIV, diabetes and eye disorders. 

Industry experts will hold roundtable discussions on hot button business issues affecting the industry including commercialization strategies, value creation and emerging regulations from the Food and Drug Administration as well the Securities and Exchange Commission.  One-on-one meetings will be arranged between investors and corporate management.

 Last year, new deals between biotech and pharmaceutical companies soared 57 percent, to a record 495, and deals between biotech companies jumped 18 percent.  Merger and acquisition activity also set a new record, with 153 deals, up 16 percent.  Dr. Corr will discuss how collaboration and partnership within biomedical research and development firms increase productivity and optimize resources.

Dr. Corr spent more than 18 years as a leading researcher in molecular biology and pharmacology at Washington University before holding senior leadership positions in research, development and discovery at Warner-Lambert Company and Monsanto/Searle. He is currently responsible for aligning Pfizer’s worldwide research and development organization with licensing activities, science and medical advocacy, global medical relations and science policy.

 “The demand for solutions to an ever-growing list of medical problems is too great for any of us to handle alone, so we must have a rich network of partnerships to succeed,” says Dr. Corr. “Industry, government, academia and others must combine their different missions, capabilities, resources and strengths to encourage innovation and productivity for the benefit of all.”

BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.

For more information about BIO CEO & Investor Conference 2005 or to register on-line, please visit www.ceo.bio.org  

###